New siRNA Cholesterol Drug Shows 83% Triglyceride Reduction in Two-Year Data
Arrowhead's REDEMPLO cuts triglycerides by 83% in rare disorder patients, with global approvals accelerating and no pancreatitis events over two years.
Summary
Arrowhead Pharmaceuticals has launched REDEMPLO, an FDA-approved RNA-silencing drug for familial chylomicronemia syndrome, a rare genetic condition causing dangerously high triglycerides and life-threatening pancreatitis. Early commercial uptake shows about 180 patients treated and 30 new prescriptions weekly. Two-year clinical data reported an 83% median triglyceride reduction with no acute pancreatitis events, a meaningful safety and efficacy signal. The drug works by silencing the APOC3 gene using siRNA technology, representing a novel approach to managing severe lipid disorders. Regulatory approvals are expanding globally across Australia, China, Canada, and Europe. Priced at $45,000 per year, access remains a practical concern for many patients.
Detailed Summary
Arrowhead Pharmaceuticals has disclosed early commercial and clinical data for REDEMPLO (plozasiran), its newly approved siRNA therapy targeting familial chylomicronemia syndrome, a rare inherited disorder characterized by extremely elevated triglycerides and recurrent acute pancreatitis. This launch represents a meaningful milestone in the application of RNA interference technology to cardiovascular and metabolic disease.
The core clinical finding is striking: two-year Phase 2b open-label extension data showed an 83% median reduction in triglycerides, with zero adjudicated acute pancreatitis events across the observation period. For a condition where pancreatitis attacks can be life-threatening and recurrent, this represents a potentially transformative outcome for affected patients.
The mechanism — silencing the APOC3 gene via small interfering RNA — reflects a broader shift in lipid management toward targeting upstream genetic drivers rather than downstream metabolic byproducts. This approach may inform future therapies for more common lipid disorders, including hypertriglyceridemia in the general population.
Commercially, early uptake is modest but growing, with roughly 180 patients receiving treatment and approximately 30 new prescriptions per week. Global regulatory momentum is building, with approvals in Australia and China already secured, a positive European opinion issued, and Canadian availability expected later in 2026. The $45,000 annual price tag positions it as a premium therapy, which will likely constrain access despite clinical promise.
Arrowhead also initiated a Phase 1/2a trial for ARO-DIMER-PA, its first dual-target RNAi candidate, signaling pipeline expansion beyond single-gene silencing. For health-conscious readers, this news is most relevant as a signal of how gene-silencing platforms are maturing into approved, real-world therapies for metabolic and cardiovascular conditions — a trajectory with implications for future longevity-focused interventions.
Key Findings
- REDEMPLO achieved 83% median triglyceride reduction over two years with no pancreatitis events reported.
- siRNA gene-silencing targets APOC3, a key regulator of triglyceride metabolism, representing a novel drug class.
- Approximately 180 patients treated since FDA approval in November 2025, with 30 new prescriptions weekly.
- Global approvals secured in Australia and China; European Commission decision and Canadian launch expected in 2026.
- Arrowhead initiated its first dual-target RNAi drug trial, expanding the gene-silencing pipeline.
Methodology
This is a news report summarizing a corporate earnings release and early commercial update, not a peer-reviewed study. Evidence basis includes company-reported Phase 2b open-label extension data and regulatory announcements. Clinical findings should be verified against published trial data or FDA review documents.
Study Limitations
Data reported are from a company earnings call and open-label extension, not a blinded randomized controlled trial, limiting causal interpretation. The $45,000 annual cost and rare disease indication restrict direct applicability to most health-optimizing adults. Long-term cardiovascular outcome data beyond triglyceride reduction have not yet been reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.